Article on SA with positive mention of IPIX: 3
Post# of 72447
(Total Views: 222)
Posted On: 08/11/2017 11:15:03 AM
Article on SA with positive mention of IPIX:
3 Things In Biotech You Should Learn Today: August 10, 2017
Aug. 10, 2017 9:00 AM ET6 comments
by: Zach Hartman, PhD
Summary
A Roche Raf inhibitor might help in inflammatory disorders.
Innovation Pharmaceuticals nearing an endgame for an important trial.
Cellectar scores a surprising improvement in early myeloma study.
Welcome to new edition of "3 Things In Biotech You Should Learn Today," a daily digest
dedicated to helping you keep up with the recent news in the biotech and pharmaceutical
industries.
So let's get right to it!
.....
Innovation Pharmaceuticals (OTCQB:IPIX) is developing a novel antimicrobial agent
called brilacidin for the prevention of severe oral mucositis, which is where the mucosal
linings of the mouth break down due to some injury, leading to increased risk of infection
and debilitating pain.
Mucositis is a common complication from local therapy for certain cancers, like head and
neck squamous cell carcinoma, where radiation therapy is an important treatment option.
The news with IPIX is that it has completed enrollment of a phase 2 study assessing
brilacidin as a preventative therapy for mucositis, and the company anticipates a top-line
data readout in the fourth quarter of 2017.
Looking forward: The current standard of care for oral mucositis generally is pointed at
alleviating symptoms, with nothing available to address the underlying infections that lead
to the complication. Brilacidin looks like it could be an effective option in this line, so it is
important for those who are following supportive care to keep up on news like this.
......
ericpapa
Hi Zach, I hold some MEIP just recently and would like to know your comment on this stock (been searched your previous
articles in SA and couldn't find a related one. Many thanks!
10 Aug 2017, 10:16 AM
Zach Hartman, PhD, Contributor
Author’s reply » MEIP is not one that's quite on my radar, though HDAC inhibitors are certainly important for heme
diseases. Early promise, but early days for that company!
10 Aug 2017, 10:51 AM
KarinCA, Contributor
Thanks... I really like your updates.
10 Aug 2017, 03:52 PM
sheeple123jump
Hi Karin. do you have any thoughts about CLRB....
Thanks,
Tom
...and thanks Dr.Zack for the article.
10 Aug 2017, 10:22 PM
empiricst1
We IPIX longs are glad to see you throwing some light on IPIX. I read your stuff each time, Many thanks for the info/insights.
3 Things In Biotech You Should Learn Today: August 10, 2017 | Seeking... https://seekingalpha.com/article/4097221-3-th...-today-a...
3 of 4 8/11/17, 8:56 AM
10 Aug 2017, 05:42 PM
Blue Fin
Investor in IPIX, like your straight forward comments. Another Author I follow is Karen CA who has written a great articles,
covering the IPIX pipeline SEE: https://seekingalpha.c...
10 Aug 2017, 07:07 PM
3 Things In Biotech You Should Learn Today: August 10, 2017
Aug. 10, 2017 9:00 AM ET6 comments
by: Zach Hartman, PhD
Summary
A Roche Raf inhibitor might help in inflammatory disorders.
Innovation Pharmaceuticals nearing an endgame for an important trial.
Cellectar scores a surprising improvement in early myeloma study.
Welcome to new edition of "3 Things In Biotech You Should Learn Today," a daily digest
dedicated to helping you keep up with the recent news in the biotech and pharmaceutical
industries.
So let's get right to it!
.....
Innovation Pharmaceuticals (OTCQB:IPIX) is developing a novel antimicrobial agent
called brilacidin for the prevention of severe oral mucositis, which is where the mucosal
linings of the mouth break down due to some injury, leading to increased risk of infection
and debilitating pain.
Mucositis is a common complication from local therapy for certain cancers, like head and
neck squamous cell carcinoma, where radiation therapy is an important treatment option.
The news with IPIX is that it has completed enrollment of a phase 2 study assessing
brilacidin as a preventative therapy for mucositis, and the company anticipates a top-line
data readout in the fourth quarter of 2017.
Looking forward: The current standard of care for oral mucositis generally is pointed at
alleviating symptoms, with nothing available to address the underlying infections that lead
to the complication. Brilacidin looks like it could be an effective option in this line, so it is
important for those who are following supportive care to keep up on news like this.
......
ericpapa
Hi Zach, I hold some MEIP just recently and would like to know your comment on this stock (been searched your previous
articles in SA and couldn't find a related one. Many thanks!
10 Aug 2017, 10:16 AM
Zach Hartman, PhD, Contributor
Author’s reply » MEIP is not one that's quite on my radar, though HDAC inhibitors are certainly important for heme
diseases. Early promise, but early days for that company!
10 Aug 2017, 10:51 AM
KarinCA, Contributor
Thanks... I really like your updates.
10 Aug 2017, 03:52 PM
sheeple123jump
Hi Karin. do you have any thoughts about CLRB....
Thanks,
Tom
...and thanks Dr.Zack for the article.
10 Aug 2017, 10:22 PM
empiricst1
We IPIX longs are glad to see you throwing some light on IPIX. I read your stuff each time, Many thanks for the info/insights.
3 Things In Biotech You Should Learn Today: August 10, 2017 | Seeking... https://seekingalpha.com/article/4097221-3-th...-today-a...
3 of 4 8/11/17, 8:56 AM
10 Aug 2017, 05:42 PM
Blue Fin
Investor in IPIX, like your straight forward comments. Another Author I follow is Karen CA who has written a great articles,
covering the IPIX pipeline SEE: https://seekingalpha.c...
10 Aug 2017, 07:07 PM
(7)
(0)